Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Eri SHiroyama"'
Publikováno v:
SN Comprehensive Clinical Medicine. 3:201-209
Background Progression of diabetic nephropathy in type 2 diabetic patients is a factor that determines the prognosis of life. Empagliflozin and canagliflozin, two oral diabetic SGLT-2 inhibitors, have shown improved renal outcomes in type 2 diabetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e1dafa29d129fb56b3e03faad6c7777
https://doi.org/10.1007/s42399-020-00707-0
https://doi.org/10.1007/s42399-020-00707-0
Background Progression of diabetic nephropathy in type 2 diabetic patients is a factor that determines the prognosis of life. Empagliflozin and canagliflozin, two oral diabetic SGLT-2 inhibitors, have shown improved renal outcomes in type 2 diabetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::220721df05831456a1da6f89a1fca299
https://doi.org/10.21203/rs.3.rs-23179/v1
https://doi.org/10.21203/rs.3.rs-23179/v1
